COMPARISON OF ACCELERATED AND RAPID SCHEDULES FOR MONOVALENT HEPATITIS B AND COMBINED HEPATITIS A/B VACCINES IN CHILDREN WITH CANCER

REFERENCES

• Januszkiewicz D, Wysocki J, Nowak J. Hepatitis B and C virus infection in Polish children with malignancies. Eur J Pediatr 1997; 156: 454–456
   PubMed Web of Science ®Google Scholar
• Kebudi R, Ayan I, Yılmaz G, Akici F, Görgün Ö, Badur S. Seroprevalence of hepatitis B, hepatitis C, and human immunodeficiency virus infections in children with cancer at diagnosis and following therapy in Turkey. Med Pediatr Oncol 2000; 34: 102–105
   PubMedGoogle Scholar
• Sevinir B, Meral A, Gunay U, Ozkan T, Ozuysal S, Sinirtas M. Increased risk of chronic hepatitis in children with cancer. Med Pediatr Oncol 2003; 40: 104–110
   PubMedGoogle Scholar
• Berberoglu S, Buyukpamukcu M, Sarialioglu F, Akyuz C, Ilhan I. Hepatitis B vaccination in children with cancer. Pediatr Hematol Oncol 1995; 12: 171–178
   PubMed Web of Science ®Google Scholar
• Goyal S, Pai S K, Kelkar R, Advani S H. Hepatitis B vaccination in acute lymphoblastic leukemia. Leuk Res 1998; 22: 193–195
   PubMed Web of Science ®Google Scholar
• Guptan R C, Thakur V, Safary A, Sarin S K. Immunogenicity and reactogenicity of a combined high dose hepatitis A and hepatitis B vaccine, compared to that of Twinrix in healthy Indian children. Vaccine 2002; 20: 2102–2106
   PubMed Web of Science ®Google Scholar
• Gonzales R P, Jolley C. Infections of the liver. Rudolphs Pediatrics21, C D Rudolph, A M Rudolph, M K Hostetter, G Lister, N J Siegel. McGraw Hill, New York 2002; 1495–1501
   Google Scholar
• Kanra G, Tezcan S, Badur S. Turkish National Study Team. Hepatitis A seroprevalence in a random sample of the Turkish population by simultaneous EPI cluster and comparison with surveys in Turkey. Turk J Pediatr 2002; 44: 204–210
   PubMed Web of Science ®Google Scholar
• Koksal Y, Yalcin B, Aydin G B. Immunogenicity of hepatitis a vaccine in children with cancer. Pediatr Hematol Oncol 2006; 23: 619–624
   PubMed Web of Science ®Google Scholar
• Zuckerman J N. The place of accelerated schedules for hepatitis A and B vaccinations. Drugs 2003; 63: 1779–1784
   PubMed Web of Science ®Google Scholar
• Akyol H, Sarialioglu F, Buyukpamukcu M, Karadeniz C, Akyuz C, Kutluk T. Hepatitis-B virus infections in pediatric patients receiving anti-cancer chemotherapy. Turk J Cancer 1990; 20: 104–108
   Google Scholar
• Kumar A, Misra P K, Rana G S, Mehrotra R. Infection with hepatitis A, B, delta, and human immuno-deficiency viruses in children receiving cycled cancer chemotherapy. J Med Virol 1992; 37: 83–86
   PubMed Web of Science ®Google Scholar
• Polychronopoulou-Androulakaki S, Panagiotou J P, Kostaridou S, Kyratzopoulou A, Haidas S. Immune response of immunocompromised children with malignancies to a recombinant hepatitis B vaccine. Pediatr Hematol Oncol 1996; 13: 425–431
   PubMed Web of Science ®Google Scholar
• Bosnak M, Dikici B, Bosnak V, Haspolat K. Accelerated hepatitis B vaccination schedules in childhood. Pediatr Int 2002; 44: 663–665
   PubMed Web of Science ®Google Scholar
• Kaya A, Erol S, Tasyaran M A, Aktas O, Yılmaz S. Early antibody response of 3-weeks hepatitis B vaccination schedule. Türkiye Tıp Dergisi 1997; 2: 98–101
   Google Scholar
• Marchou B, Excler J L, Bourderioux C. A 3-week hepatitis B vaccination schedule provides rapid and persistent protective immunity: a multicenter, randomized trial comparing accelerated and classic vaccination schedules. J Infect Dis 1995; 172: 258–260
   PubMed Web of Science ®Google Scholar
• Nothdurft H D, Dietrich M, Zuckerman J N. A new accelerated vaccination schedule for rapid protection against hepatitis A and B. Vaccine 2002; 20: 1157–1162
   PubMed Web of Science ®Google Scholar
• Saltoglu N, Inal A S, Tasova Y, Kandemir O. Comparison of the accelerated and classic vaccination schedules against hepatitis B: three-week hepatitis B vaccination schedule provides immediate and protective immunity. Ann Clin Microbiol Antimicrobiol 2003; 2: 10
   PubMedGoogle Scholar
• Santagostino E, Mannucci P M, Gringeri A. Accelerated schedule of hepatitis B vaccination in patients with hemophilia. J Med Virol 1993; 41: 95–98
   PubMed Web of Science ®Google Scholar
• Duval B, Gilca V, Boulianne N, Deceuninck G, Rochette L, De Serres G. Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8–10-year-old children. Vaccine 2005; 23: 4082–4087
   PubMed Web of Science ®Google Scholar
• Roberton D, Marshall H, Nolan T M. Reactogenicity and immunogenicity profile of a two-dose combined hepatitis A and B vaccine in 1–11-year-old children. Vaccine 2005; 23: 5099–5105
   PubMed Web of Science ®Google Scholar
• Kallinowski B, Jilg W, Buchholz L, Stremmel W, Engler S. Immunogenicity of an accelerated vaccination regime with a combined hepatitis A/B vaccine in patients with chronic hepatitis C. Z Gastroenterol 2003; 41: 983–990
   PubMed Web of Science ®Google Scholar
• Ferreira C T, Leite J C, Taniguchi A, Vieira S M, Pereira-Lima J, da Silveira T R. Immunogenicity and safety of an inactivated hepatitis A vaccine in children with Down syndrome. J Pediatr Gastroenterol Nutr 2004; 39: 337–340
   PubMed Web of Science ®Google Scholar
• Gunther M, Stark K, Neuhaus R, Reinke P, Schroder K, Bienzle U. Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. Transplantation 2001; 71: 477–490
   PubMed Web of Science ®Google Scholar
• Riedemann S, Reinhardt G, Ibarra H, Frosner G G. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in healthy toddlers and children in Chile. Acta Paediatr 2004; 93: 412–414
   PubMed Web of Science ®Google Scholar
• Santagostino E, Gringeri A, Rocino A, Zanetti A, de Biasi R, Mannucci P M. Patterns of immunogenicity of an inactivated hepatitis A vaccine in anti-HIV positive and negative hemophilic patients. Thromb Haemost 1994; 72: 508–510
   PubMed Web of Science ®Google Scholar
• Majda-Stanislawska E, Bednarek M, Kuydowicz J. Immunogenicity of inactivated hepatitis A vaccine in children with chronic liver disease. Pediatr Infect Dis J 2004; 23: 571–574
   PubMed Web of Science ®Google Scholar